This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

T. KOLAKOWSKA, MD; A. O. Williams, MD; M. Ardern, MD
Department of Psychiatry University of Oxford Littlemore Hospital Oxford, England 0X4 4XN

Arch Gen Psychiatry. 1986;43(6):614.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

There was an error in the editorial processing of our letter in the September issue of the Archives (p 925). The abbreviation FPZd was expanded incorrectly to read "flupenthixol" in line 7 of the "Results" section, and should have read "fluphenazine." ("In none of the 18 patients with TD did the current dose of neuroleptics exceed 37.5 mg/wk of fluphenazine decanoate or its equivalent.")

Also, the following two paragraphs that were meant to clarify the results were inadvertently deleted and are now presented for the reader's information.

The deficit of TD among patients receiving large doses of neuroleptics is in keeping with the concept of "covered" dyskinnesia,¹ ie, dyskinesia suppressed by the current medication.

We would like to emphasize two methodological points in relation to our findings: (1) that the "true" prevalence of TD may be underestimated in samples that include patients treated with large doses of . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?